We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Follow-On Biologics Legislation Necessary to Pass, Expert Says
Follow-On Biologics Legislation Necessary to Pass, Expert Says
September 4, 2007
The agency needs new legislation to approve follow-on biologics that addresses patent protection, approval standards, exclusivity and product names, Michael Labson, a partner with Covington & Burling, said at the Third Annual FDA Regulatory and Compliance Symposium at Harvard University.